Reduction of glucose uptake from the gut by SGLT1 inhibitors is being explored for treatment of diabetes and obesity (Wagman and Nuss, 2001; Asano et al., 2004). The gene discussed is SLC5A1; the disease is obesity due to melanocortin 4 receptor deficiency.